Cerevel Therapeutics Holdings (CERE) was Downgraded to a Hold Rating at Sidoti
In a report issued on November 25, Sidoti from Sidoti downgraded Cerevel Therapeutics Holdings (CERE) to Hold. The company’s shares closed last Monday at $14.20.
Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Moderate Buy with an average price target of $17.50.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ARYA Sciences Acquisition Corp II is a blank check company.